Frequency Therapeutics is a biotechnology company developing and commercializing its innovative platform technology to address a substantial and unmet clinical need–hearing loss. The company's platform technology is based on discoveries in stem cell biology and has has shown great promise in reversing sensory hearing loss, a malady that impacts over 1 billion people globally and which currently has no therapeutic solution.

Frequency Therapeutics was co-founded by two world-renowned scientists: MIT Institute Professor Robert S. Langer and Jeffrey Karp, Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. Frequency is translating ground breaking discoveries made in the area of cell programming. They've solved a key bottleneck in bringing stem cell programming to patients–namely by harnessing rapidly translatable small molecule combinations that selectively target entrenched stem cells in the body.